Table: Attractive Targets
Product pipelines at these companies could attract suitors or partners:
Has promising drugs in development, including ranolazine, for angina, which could launch in 2003 and top $500 million in sales.
Its HIV drug was just approved, and a Hepatitis B treatment is in development. Combined sales of the two could top $1 billion.
Awaiting Food & Drug Administration approval for Replagal, a treatment for a rare metabolic disease. This could blossom into a $300 million drug.
Its 50-50 partnership with Hoffmann-La Roche is developing "fusion inhibitor" drugs for HIV. The first could exceed $400 million in revenues.
Data: Mehta Partners, Lehman Brothers & SG Cowen